Today MEI Pharma announced that enrollment for their phase 2 trial for patients who are elderly, newly diagnosed with AML (acute myeloid leukemia) is complete. This trial enrolled 50 patients extremely fast since August 1st, when they only had 14 total enrollments. Since then, the company announced that they achieved 8 (CR) complete remissions, or 57% in November with no progressions...
The company will give an update at ASH on December 6th, for 33 patients who have been enrolled, and the other 17 would be deemed too early to evaluate. This is all positive news, as the patient responses were improving, as the trial progressed. If the 57% of complete responses create a durable overall survival (OS) of 12 months or longer, then the combination of Pracinostat / Vidazza for AML, would improve on the current therapy for patients where there is an unmet need. Current median overall survival for Vidazza alone, in a similar patient category is 10.4 (12.1 with sensitivity analysis) months in this trial Phase-III-Study-AML-001-VIDAZA. Thank you for reading.
The company will give an update at ASH on December 6th, for 33 patients who have been enrolled, and the other 17 would be deemed too early to evaluate. This is all positive news, as the patient responses were improving, as the trial progressed. If the 57% of complete responses create a durable overall survival (OS) of 12 months or longer, then the combination of Pracinostat / Vidazza for AML, would improve on the current therapy for patients where there is an unmet need. Current median overall survival for Vidazza alone, in a similar patient category is 10.4 (12.1 with sensitivity analysis) months in this trial Phase-III-Study-AML-001-VIDAZA. Thank you for reading.
No comments:
Post a Comment